23:48:10 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-05-25 Kvartalsrapport 2023-Q3
2023-02-23 Kvartalsrapport 2023-Q2
2022-11-24 Ordinarie utdelning SELECT B 0.00 SEK
2022-11-23 Årsstämma 2023
2022-11-16 Kvartalsrapport 2023-Q1
2022-08-30 Bokslutskommuniké 2022
2022-05-24 Kvartalsrapport 2022-Q3
2022-02-24 Kvartalsrapport 2022-Q2
2021-11-25 Ordinarie utdelning SELECT B 0.00 SEK
2021-11-24 Årsstämma 2022
2021-11-18 Kvartalsrapport 2022-Q1
2021-08-31 Bokslutskommuniké 2021
2021-05-25 Kvartalsrapport 2021-Q3
2021-02-26 Kvartalsrapport 2021-Q2
2020-11-27 Kvartalsrapport 2021-Q1
2020-11-26 Ordinarie utdelning SELECT B 0.00 SEK
2020-11-26 Årsstämma 2021
2020-08-27 Bokslutskommuniké 2020
2020-05-20 Kvartalsrapport 2020-Q3
2020-02-20 Kvartalsrapport 2020-Q2
2019-11-21 Ordinarie utdelning SELECT B 0.00 SEK
2019-11-20 Årsstämma 2020
2019-11-07 Kvartalsrapport 2020-Q1
2019-08-29 Bokslutskommuniké 2019

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriLäkemedel & Handel
SelectImmune Pharma är ett läkemedelsbolag. Bolaget ämnar utveckla läkemedelskandidater med fokus på endogena inflammatoriska medel och bakteriemolekyler. Produkterna är inriktade mot att förstärka immunsystemet och används huvudsakligen för behandling av infektionssjukdomar, samt kronisk inflammation. Bolaget grundades 2017 och innehar störst verksamhet inom den nordiska marknaden.
2022-03-29 21:38:00

As of March 29[th], SelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi®) to buy Kineret® (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome.

Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation and infection in animal models of cystitis and SelectImmune Pharma is now pursuing clinical trials to further assess the clinical efficacy in these areas.

Kineret (anakinra) is a trademark of Sobi, who markets the drug for various inflammatory conditions, whereas SelectImmune Pharma's patents cover the use of anakinra for the treatment of cystitis and bladder pain syndrome specifically.

The agreement defines that SelectImmune Pharma will conduct clinical trials in these areas with Sobi as the provider of drug and placebo. The parties have the intention to discuss a potential commercialization agreement for the indications protected by SelectImmune Pharma's patent rights.

"We are delighted to have the purchase agreement in place to be able to pursue the studies of the different clinical indications where anakinra has the potential to add value for patients," says Catharina Svanborg, Chairman, SelectImmune Pharma.

"This agreement is of great value to SelectImmune Pharma and we very much look forward to seeing the results of these studies" says Ann Gidner, CEO, SelectImmune Pharma.

For more information, please contact

Catharina Svanborg

Chairman

SelectImmune Pharma AB

Phone +46 709 42 65 49

catharina.svanborg@med.lu.se

Ann Gidner

CEO

SelectImmune Pharma AB

Phone +46 768 17 14 14

ann.gidner@selectImmune.com

This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-03-2022 21:38 CET.